Olaparib is a targeted therapy drug that belongs to the class of PARP inhibitors (Poly ADP-Ribose Polymerase inhibitors). It is specifically designed to exploit the weaknesses in cancer cells' DNA repair mechanisms, making it a potent weapon in the fight against certain types of cancer.
